Fig. 1From: Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) studyPatient disposition. Flow chart showing the number of patients who were enrolled, commenced rituximab-maintenance treatment, and completed the rituximab-maintenance treatment. AE adverse event, PD progressive diseaseBack to article page